PROCLIPI国际早期蕈样肉芽肿登记研究:多数患者存在显著诊断延迟
PROCLIPI研究纳入来自15个国家29个中心的430例患者,其中348例经中央复核确认为早期蕈样肉芽肿(MF)。多数为经典型MF(81.6%),CD4表型占88.2%,滤泡型MF占17.8%。从首发症状到初次诊断的诊断延迟常见(85.6%),中位延迟36个月(四分位距12-90)。
要点
- 早期MF患者中诊断延迟普遍,85.6%存在延迟,中位延迟36个月。
- 多数患者为经典型MF(81.6%),CD4表型占88.2%。
- 初诊时49.4%为IA期,42.8%为IB期,7.8%为IIA期(淋巴结增大)。
核心结论
- 该早期MF队列正在随访以识别预后因素,可能通过识别疾病进展风险患者来改善管理和生存。
研究设计与样本
- PROCLIPI研究为基于网络的数据收集系统,收集早期MF患者初诊时及每年预设数据集。
- 共纳入来自15个国家29个中心的430例患者,其中348例经中央复核确认为早期MF。
主要发现
- 多数患者为经典型MF(81.6%),CD4表型占88.2%,滤泡型MF占17.8%。
- 初诊时49.4%为IA期,42.8%为IB期,7.8%为IIA期(淋巴结增大)。
- 从首发症状到初次诊断的诊断延迟常见(85.6%),中位延迟36个月(四分位距12-90)。
关键数值与推荐
- 诊断延迟定义为从首发症状发展到初次诊断,85.6%的患者存在延迟,中位延迟36个月(四分位距12-90)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Survival in mycosis fungoides (MF) is varied and may be poor. The PROCLIPI (PROspective Cutaneous Lymphoma International Prognostic Index) study is a web-based data collection system for early-stage MF with legal data-sharing agreements permitting international collaboration in a rare cancer with complex pathology. Clinicopathological data must be 100% complete and in-built intelligence in the database system ensures accurate staging. OBJECTIVES: To develop a prognostic index for MF. METHODS: Predefined datasets for clinical, haematological, radiological, immunohistochemical, genotypic, treatment and quality of life are collected at first diagnosis of MF and annually to test against survival. Biobanked tissue samples are recorded within a Federated Biobank for translational studies. RESULTS: In total, 430 patients were enrolled from 29 centres in 15 countries spanning five continents. Altogether, 348 were confirmed as having early-stage MF at central review. The majority had classical MF (81·6%) with a CD4 phenotype (88·2%). Folliculotropic MF was diagnosed in 17·8%. Most presented with stage I (IA: 49·4%; IB: 42·8%), but 7·8% presented with enlarged lymph nodes (stage IIA). A diagnostic delay between first symptom development and initial diagnosis was frequent [85·6%; median delay 36 months (interquartile range 12-90)]. This highlights the difficulties in accurate diagnosis, which includes lack of a singular diagnostic test for MF. CONCLUSIONS: This confirmed early-stage MF cohort is being followed-up to identify prognostic factors, which may allow better management and improve survival by identifying patients at risk of disease progression. This study design is a useful model for collaboration in other rare diseases, especially where pathological diagnosis can be complex.
引用
- Scarisbrick JJ, Quaglino P, Prince HM, et al. The PROCLIPI international registry of early-stage mycosis fungoides identifies substantial diagnostic delay in most patients. Br J Dermatol. 2018. PMID: 30267549. doi:10.1111/bjd.17258
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。